Azmi Nabulsi - Sep 1, 2022 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
Chief Operating Officer
Signature
/s/ Larry Miller, Attorney-in-Fact for Azmi Nabulsi
Stock symbol
PHAT
Transactions as of
Sep 1, 2022
Transactions value $
$0
Form type
4
Date filed
9/2/2022, 04:05 PM
Previous filing
May 20, 2022
Next filing
Jan 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Award $0 +7.5K +21.76% $0.00 42K Sep 1, 2022 Direct F1, F2
holding PHAT Common Stock 2.36K Sep 1, 2022 by 401(k) F3
holding PHAT Common Stock 786K Sep 1, 2022 by Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Includes 1,093 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022.
F3 Includes 1,511.80 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.